Skip to navigation Skip to content

Participate in a Clinical Trial

Without the participation of people with MS, it would be impossible to develop new and better therapies and other interventions.

Clinical Trials in MS


The latest clinical research in MS, including trials funded by the Society and trials in progressive MS.

Read more

Read more

Posting a Trial

If you would like us to post a study on these pages, please email studies@nmss.org to find out what information you need to submit for review.

Share




Clinical trials help to determine if treatments are safe and effective. Studies are monitored to ensure that the rights and safety of all participants are protected. Make an informed decision before agreeing to participate. Read more in our Guide to Participating in Clinical Trials.

Clinical Trials In Your Area

Interested in clinical trials? Simply search by state, type of MS or keyword and see what’s going on in your area.

  1. Clinical Trial: Tai Chi and Mindfulness Training

    Investigators are recruiting people with all subtypes of MS (participants need to capable of standing and moving unaided for a minimum of 15 minutes at a time) to investigate the impact of mindfulness training on balance and wellbeing in individuals with MS. This is a communit...
  2. Clinical Trial: Computerized Cognitive Training

    The purpose of this study is to evaluate two computerized brain training tools, which include light physical activity, to see if they can help improve cognitive functions, such as memory and attention, for people with MS. Participants would complete a set of tests (physical an...
  3. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg.  Please note: In response to the recent developments of the COVID-19 pandemic, sites are implementing me...
  4. Research Study: Fatigue

    Please note: This is not a clinical trial of an intervention, but rather a research study.  The purpose of this study is to systematically evaluate the relationship between fatigue severity, autonomic (involuntary) symptom burden, and autonomic physiological markers in MS p...
  5. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg.  Please note: In response to the recent developments of the COVID-19 pandemic, sites are implementing me...
  6. Clinical Trial: Ofatumumab

    A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient- reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. FDA Approved medication (Brand na...
  7. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg. 
  8. Research Study: Physiologic dysfunction in MS-related Fatigue

    This research study is designed to assess whether physiologic dysfunction contributes to fatigue in people with MS. This connection will help guide routine neurological treatment fatigue in MS in the future.  Physiologic testing includes measurement of a person’s pupil functi...
  9. Clinical Trial: Ocrelizumab

    This is a double blind, multicenter study to evaluate the effectiveness, safety and pharmacokinetics (how the drug moves within the body) of a higher dose of ocrelizumab taken via intravenous infusion every 24 weeks in people with relapsing MS, in comparison to the approved 60...
  10. Clinical Trial: Ozanimod for Cognitive Function

    This is a multicenter, single-arm, open-label study to describe the change from baseline in cognitive processing speed in subjects with relapsing multiple sclerosis (RMS) treated with ozanimod HCl 1 mg at 3 years. All enrolled subjects will receive orally administered ozanimod...
  11.  |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

Share


The National MS Society is Here to Help

Newly Diagnosed
If you or somone close to you has recently been diagnosed, access our MS information and resources.

Start Here

Start Here
© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.